Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
Sign Up to like & getrecommendations! Published in 2019 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2019.05.002
Abstract: Recurrent or metastatic head and neck squamous-cell carcinomas (R/M HNSCC) are a group of cancers with a very poor prognosis. Many clinical trials testing novel target therapies in this setting are currently ongoing. We performed… read more here.
Keywords: systematic review; metastatic head; recurrent metastatic; target therapies ... See more keywords
Biological Treatments and Target Therapies for Pediatric Respiratory Medicine: Not Only Asthma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.837667
Abstract: We present a description of pediatric pneumology biological medications and other target therapies. The article aims at introducing the importance of a molecular approach to improve treatments. The first item treated was T2-High asthma and… read more here.
Keywords: target therapies; asthma; therapies pediatric; biological treatments ... See more keywords
The FGFR2c/PKCε Axis Controls MCL-1-Mediated Invasion in Pancreatic Ductal Adenocarcinoma Cells: Perspectives for Innovative Target Therapies
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10071652
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy whose main characterizations are Kirsten Rat Sarcoma-activating mutations (KRAS) and a highly aggressive phenotype. Based on our recent findings demonstrating that the highly aberrant expression of the… read more here.
Keywords: target therapies; pkc axis; innovative target; ductal adenocarcinoma ... See more keywords
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms232213898
Abstract: The MET gene, known as MET proto-oncogene receptor tyrosine kinase, was first identified to induce tumor cell migration, invasion, and proliferation/survival through canonical RAS-CDC42-PAK-Rho kinase, RAS-MAPK, PI3K-AKT-mTOR, and β-catenin signaling pathways, and its driver mutations,… read more here.
Keywords: target therapies; met signaling; resistance; pathways resistance ... See more keywords